Diabetes Drug Avandia Increases Heart Attack Risk: Report

by VR Sreeraman on September 12, 2007 at 6:13 PM
Diabetes Drug Avandia Increases Heart Attack Risk: Report

An analysis of four clinical trials involving more than 14,000 patients found that diabetes medication Avandia (rosiglitazone) taken over a lengthy period of time increases the risk of heart attack by 42 percent, a report released Tuesday said.

It marks one of the first studies to look at how use for one year or longer of Avandia, in patients with type 2 diabetes, affects risk of heart attack, heart failure and mortality, according to authors of the study in the September 12 issue of the Journal of The American Medical Association (JAMA).


The Food and Drug Administration recently required a label to be put on Avandia, made by British drugmaker GlaxoSmithKline, and similar treatments, warning of increased risk of heart failure.

An analysis of 42 short-term clinical studies published in May in the New England Journal of Medicine found that Avandia boosts heart attack risk by 43 percent.

"The public health impact of potential harm with rosiglitazone is substantial," said Sonal Singh, MD, lead author and an assistant professor of internal medicine at Wake Forest. "Regulatory agencies should urgently evaluate whether this drug should remain on the market."

"There is no need for physicians, health plans or patients to wait for regulatory action," added Curt Furberg, a co-author of the report. "On the contrary, they should take prompt action and restrict the use of Avandia, especially since safer alternatives are available."

Source: AFP
Font : A-A+



Recommended Readings

Latest Drug News

Anti-Obesity Drugs' Impact on Osteoarthritis Survival
The impact of anti-obesity drugs on survival rates among osteoarthritis patients is under scrutiny, evaluating their potential influence on mortality risks.
Can a Needle-Free Patch Transform Zika Protection?
Researchers create needle-free Zika vaccine patch, using HD-MAP tech, aiming to protect against fatal virus spread by mosquitoes.
Prolonging Market Exclusivity of Brand-name Insulin
Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.
FDA Boosts Orphan Drug Designations for Myelofibrosis Treatments
The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.
Anti-Rheumatic Drugs May Help Prevent Thyroid Disease
The most significant decrease in autoimmune thyroid disease risk was observed in rheumatoid arthritis patients receiving immunomodulatory drugs or 'biological DMARDs'.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Diabetes Drug Avandia Increases Heart Attack Risk: Report Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests